Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shionogi has launched Cuvposa (glycopyrrolate) oral solution for the reduction of chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
Subscribe to our email newsletter
The company has received the US Food and Drug Administration approval for Cuvposa in July 2010 on the basis of a Phase III study of 38 subjects which showed that 75% of children and adolescents treated with Cuvposa experienced an improvement in symptoms, versus 11% who received placebo.
Shionogi will sign a partnership with Diplomat Specialty Pharmacy to grant caregivers convenient access to the newly-available treatment via a patient’s physician.
Shionogi chief medical officer Donald Manning said unlike tablet formulations, liquid Cuvposa does not require compounding by a pharmacist before it is administered by caregivers, providing families with a new approach to treating chronic severe drooling in children and adolescents with neurologic conditions.